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Psoriasis is one of the most common skin disorders,
occurring in about 2-3% of the UK population. It
is thought to be due to reduced control over
epidermal cell-division by the central regulating
mechanisms, which are probably located in the
hypothalamus (Seville, 1980).
Shuster et al. (1979) suggested that there was a
low incidence of skin cancer in patients with
psoriasis, despite repeated use of known carcinogens
in treatment. They suggested that this might be due
to the reduced activity of aryl hydrocarbon
hydroxylase in both epidermis (Chapman et al.,
1979) and other tissues of subjects with psoriasis
(Chapman et al., 1980). However, it has now been
reported that there is doubt about the veracity of
these observations (Rawlins & Shuster, 1982).
Stern et al. (1979) followed 1,373 patients with
psoriasis who were treated with 8-Methoxypsoralen
phototherapy; an excess of cutaneous cancer was
reported in these patients. This was based on the
observed incidence in a different population, and
not from incidence in matched controls. There was
a suggestion that the risk of cancer in psoriatic
patients who received phototherapy was the same
as the general population. After exclusion of
patients with previous irradiation, those having a
history of skin cancer, and those with a fair skin,
there was no excess of cancer in the phototherapy-
treated patients. These results were disputed by
Morgan (1979) and Halprin (1980), who suggested
that there was over-diagnosis in the phototherapy
treated patients. Stern et al. (1980a) acknowledged
the defect of lack of controls in their study, but still
maintained that internal analysis, particularly the
alteration in the histological type of skin cancers
occurring suggested that these were not due to
enhanced diagnosis through careful follow up.
Pembroke et al. (1979) suggested that the excess
was more likely to be due to the prior treatment
both from ionising radiation and from arsenic in
the subjects who had long standing psoriasis.
A case control study of psoriatic patients (Stern
et al., 1980b) suggested that there was an increase in
skin cancer in those patients who had been treated
with topical tar or ultraviolet radiation prior to
phototherapy.
In order to check on the possible association
between psoriasis and cancer a study has been done
on records from the hospital discharge statistics in
Scotland. The work of Chapman et al. (1979, 1980)
indicated that skin and lung cancer might be
particularly reduced; it was decided to look at these
two sites, plus another where smoking was a factor
(bladder), and a site where environmental factors
were thought to be important but not smoking
(stomach). This check of selected sites was thought
preferable to examination of every site of
malignancy-which would have resulted in many
tests of significance and problems of interpretation
from fluctation in small numbers.
The availability and use of medical record linkage
methods in Scotland has been described by
Heasman & Clarke (1979). The linkage study was
carried out in 3 stages. All non-psychiatric and non-
obstetric discharge records (1968-79) which
included a diagnosis of psoriasis were linked
together to produce a file of individual patients with
this condition. The resulting 8,405 unique patient
records were then linked with the Scottish General
Register Office files of all deaths in Scotland during
1968-1979 to discover which patients had died
during this period. Finally, the same records were
linked with the Scottish National Cancer Register
files for 1968-79 to find those patients who had
been registered as having cancer of any site. Some
of these patients, apart from the small number of
children born and admitted during the period 1968-
79, may have had psoriasis for a considerable time
and had several admissions to hospital prior to
1968. It is also possible that some of these patients
could have had treatment and therefore registration
for cancer before 1968. Discharges and cancer
registrations prior to 1968 could not be identified
because the record linkage method uses surnames
and initials and these data were not included in
national statistics until 1968. The study therefore
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concerns the incidence of malignant disease in a
given period amongst a group of patients who at
some time during that period had in-patient
treatment for psoriasis.
The expected incidence of cancers in this group
was calculate by the conventional technique of
applying age, sex and calendar-specific cancer
registration rates to person years at risk. The
majority of cancer registration rates used in these
calculations were derived from the Scottish
National Cancer Register for 1968-79-i.e. the same
file as that used in the linkage to obtain the
observed incidence. There were no published rates
for malignant neoplasms of the skin other than
melanoma (ICD 173); rates for England and Wales
were therefore used. Patients included in the study
were considered "at risk" of being registered as
suffering from cancer either from 1 January 1968, or
their date of birth if this was later, until the end of
1979 or until their date of death if they died during
the period. The computer programme for
generating the person years at risk (MYCL) was
kindly provided by Hill (1972).
There were 8,405 subjects diagnosed with
psoriasis in the period 1968-79, and the average
follow-up for these subjects was 11.5 years. (The
period is slightly less than 12 years as some of the
individuals were only born after 1 January 1968
and thus were not exposed for the complete 12-year
period. Other subjects entered into the study died
before 31 December 1979 and thus contributed less
than 12 years at risk to the person years
calculation.)
Table I sets out the observed and expected
cancers in the subjects by sex, for the 4 specific
cancers examined together with all neoplasms. For
each sex Table I shows the observed, the expected
cancers, the ratio of observed-to-expected, the value
for x2 and the probability of the observed results.
Obviously, there are some important points that
need to be borne in mind before interpreting the
results. The data are based on hospital discharge
statistics, and these are not an ideal source of valid
diagnoses for patients suffering from psoriasis.
There may be particular characteristics of the
subject that determine the likelihood of their being
admitted (and it is conceivable that subjects with
cancer in whom psoriasis is also diagnosed are also
more likely to be admitted to hospital and
recognised as having psoriasis than subjects without
such cancer). There is also the suggestion,
particularly as far as the skin cancer is concerned,
that subjects with psoriasis may be under
observation by dermatologists and thus more likely
to have a skin cancer recognised and reported to
the national registration scheme. There is in
addition the confounding influence of various
treatments which has already been mentioned in the
background section; no information on prior
treatment was available for the 8,000 patients
involved.
However, bearing the above points in mind the
observed and expected figures for malignancy
indicated no clear variation for the "persons"
results. There appears to be a modest deficit in
cancers in the males and a modest excess in the
females-neither of these differences being at the
level of significance that one would wish to draw
firm conclusions (though the difference of the males
has a P value <0.025, it must be remembered that
in Table I as a whole 10 comparisons are being
made and thus a P value of - 0.05 does not
automatically indicate "significance"). The one site
with an appreciable variation from O/E=1 for
persons is stomach cancer (O/E=0.51, P<0.01).
When the data are examined by sex, the difference
is much more extreme than one would have
expected by chance in the males. This is in contrast
Table I Observed and expected cancers in patients followed through the period 1968-79, in Scotland
Persons Males Females
ICD
Site code 0 E OIE X2 p 0 E OIE X2 p 0 E OIE X2 p
Stomach 151 15 29.2 0.51 6.90 <0.01 4 18.2 0.22 11.08 <0.001 11 11.0 1.0
Lung 162 89 92.0 0.97 0.10 <0.09 66 76.1 0.87 1.34 <0.3 23 15.9 1.45 3.17 <0.1
Skin 172-3 51 43.6 1.17 1.26 <0.5 31 24.7 1.26 1.61 <0.3 20 18.9 1.06 0.06 <0.5
Bladder 188 22 19.6 1.12 0.29 <0.75 19 15.0 1.27 1.07 <0.4 3 4.6 0.65 0.56 <0.5
All 140-209 403 422.6 0.95 0.91 <0.5 201 237.0 0.84 5.72 <0.025 202 185.6 1.09 1.45 <0.3
Note: The expected figures are based upon the following:
ICD 151, 162, 172, 188 Registration rates for Scotland for 1968, 1973, and 1977.
ICD 173, Registration rates for England and Wales for 1968, 1973, and 1978.
ICD 140-209 Registration rates for Scotland for 1970, 1973, and 1977.CANCER IN PSORIASIS PATIENTS 859
to the general pattern of the results, and very
different from that in females whose observed and
expected figures are identical. It also accounts for a
large part of the deficiency in the observed figures
for all sites among males. No explanation can be
offered for this deficit of stomach cancer in the
males.
A particular point of interest was whether there
was an increase in skin cancer in these patients with
psoriasis; both for males and females the ratio of
observed to expected cancers is > 1.0, but in neither
sex it is significant.
It is concluded from these results that there is no
clear evidence of either a protective effect from the
psoriasis in itself, nor a carcinogenic effect from the
treatment that the patients have been having.
We are grateful to colleagues at the Scottish Office
Computer Services who prepared the files and
programmes for the linkage exercises, the Registrar
General for Scotland for permission to access the Scottish
mortality data, Dr M. Heasman for advice, and Mrs J.
Folwell for secretarial help.
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